Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

doi:10.1001/jamaoncol.2020.2288

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

JAMA oncology - 1 Aug 2020

Puzanov Igor, Ribas Antoni, Robert Caroline, Schachter Jacob, Nyakas Marta, Daud Adil, Arance Ana, Carlino Matteo S, O'Day Steven J, Long Georgina V, Margolin Kim A, Dummer Reinhard, Schadendorf Dirk, Lutzky Jose, Ascierto Paolo A, Tarhini Ahmad, Lin Jianxin, Mogg Robin, Homet Moreno Blanca, Ibrahim Nageatte, Hamid Omid

Abstract excerpt

Importance: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E/K-mutant melanoma is not well established. Objective: To assess the association of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy with response to pembrolizumab. Design, Setting, and Participants: This study is a post hoc subgroup...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Double-Blind Method

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32672795
DOI: 10.1001/jamaoncol.2020.2288
PMCID: PMC7366279

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.PMID 32672795Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.